Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well avelumab with or without cetuximab work in treating
patients with skin squamous cell cancer that has spread to other places in the body.
Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread.